Predictors of Hormone Response in ER-Unknown Breast Tumours
Author Information
Author(s): V. Hug, H. Thames, S. Bentzen
Primary Institution: The University of Texas M. D. Anderson Cancer Center
Hypothesis
Can clonogenicity and hormone-induced proliferative response serve as reliable predictors of hormone response in ER-unknown breast tumours?
Conclusion
Clonogenicity and hormone-induced proliferative response can effectively predict the response to endocrine treatments in patients with ER-unknown breast tumours.
Supporting Evidence
- Clonogenicity was a more powerful predictor of hormonal dependence than oestrogen receptor status.
- 88% of patients could be correctly classified using the combined criteria of clonogenicity and hormone-induced proliferative response.
- All but two of the oestrogen receptor-negative tumours responded to growth stimulation.
Takeaway
Some breast tumours can respond to hormone treatments even if they don't have a known estrogen receptor, and we can figure this out by looking at how they grow in the lab.
Methodology
The study assessed the clonogenicity and hormone-induced proliferative response of tumours from 122 patients with stage IV breast carcinoma.
Limitations
The study primarily focused on ER-unknown tumours, and the predictive value of the tests may not apply to ER-positive or ER-negative tumours.
Participant Demographics
Patients with stage IV breast carcinoma, including 15 with ER-positive and 17 with ER-unknown tumours.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website